Vasudev, NS orcid.org/0000-0001-8470-7481, Ainsworth, G, Brown, S orcid.org/0000-0002-7975-7537 et al. (17 more authors) (2021) LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM). In: ESMO Congress 2021, 16-21 Sep 2021, Virtual.
Metadata
Item Type: | Conference or Workshop Item |
---|---|
Authors/Creators: |
|
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 10 Dec 2021 16:01 |
Last Modified: | 10 Dec 2021 16:01 |
Status: | Published |
Identification Number: | 10.1016/j.annonc.2021.08.2105 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:179364 |
Download not available
A full text copy of this item is not currently available from White Rose Research Online